Inclusion Criteria:

- Histologic or cytologic history diagnosis of primary ovarian, primary peritoneal or
tubal carcinoma

- Asymptomatic from ovarian cancer

- Evidence of recurrent ovarian, peritoneal or tubal carcinoma

- Tumor sample must be positive for ER and/or PR

- 18 years of age or older

- ECOG performance status of less than or equal to 1

- Must be able to tolerate oral intake

Exclusion Criteria:

- Known hypersensitivity to Iressa or any of the excipients of this product

- Other coexisting malignancies or malignancies diagnosed within the last 5 years

- Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital
or St. John's wort

- Treatment with a non-approved or investigational drug within 30 days

- Any unresolved chronic toxicity greater than CTC grad 2 from previous anticancer
therapy (except alopecia)

- Incomplete healing from previous oncologic or other major surgery

- Serum creatinine level greater than CTC grade 2

- Pregnant or breast feeding

- Severe uncontrolled systemic disease

- Significant clinical disorder or laboratory finding that makes it potentially unsafe
for the subject to participate

- Patients currently receiving other investigational antineoplastic agents, on systemic
chemotherapy or under radiation therapy treatment

- Patients previously treated with anastrozole or other aromatase inhibitor

- Unable to tolerate oral medications

- Clinical and/or radiographic evidence of current or impending bowel obstruction